Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 2, 2017, Pages 547-553

  Viasus, Diego ^a   Simonetti, Antonella F ^b   Garcia Vidal, Carolina ^b,c   Niubó, Jordi ^b,d   Dorca, Jordi ^b,d   Carratalà, Jordi ^b,c,d  

^a UNIVERSIDAD DEL NORTE   (Colombia)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Spanish Network for Research in Infectious Diseases ^*  (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; INFLUENZA VACCINE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC DEESCALATION; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CLINICAL FEATURE; CLINICAL OUTCOME; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMPYEMA; FEMALE; GRAM STAINING; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; RETROSPECTIVE STUDY; SEPTIC SHOCK; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; TACHYPNEA; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; HOSPITALIZATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PENICILLINS; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 85014558491     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw441     Document Type: Article

References (23)

1. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
2. Jain S, Self WH, Wunderink RG et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373: 415-27.
3. Rosón B, Carratalà J, Dorca J et al. Etiology, reasons for hospitalization, risk classes and outcomes of patients with community-acquired pneumonia hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158-65.
4. Garcia-Vidal C, Ardanuy C, Tubau F et al. Pneumococcal pneumonia presenting with septic shock: host-and pathogen-related factors and outcomes. Thorax 2010; 65: 77-81.
5. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011; 17 Suppl 6: E1-59.
6. Sordé R, Falcó V, Lowak M et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011; 171: 166-72.
7. Johansson N, Kalin M, Tiveljung-Lindell A et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50: 202-9.
8. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 Suppl 1: i3-10.
9. Laxminarayan R, Duse A, Wattal C et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013; 13: 1057-98.
10. Dellit TH, Owens RC, McGowan JE et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
11. Carratalà J, Garcia-Vidal C, Ortega L et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia. A randomized controlled trial. Arch Intern Med 2012; 172: 922-8.
12. Bosso JA, Drew RH. Application of antimicrobial stewardship to optimise management of community acquired pneumonia. Int J Clin Pract 2011; 65: 775-83.
13. Carugati M, Franzetti F, Wiemken T et al. De-escalation therapy among bacteraemic patients with community-acquired pneumonia. Clin Microbiol Infect 2015; 21: 936.e11-8.
14. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
15. Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-7.
16. Shime N, Kosaka T, Fujita N. De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli. Infection 2013; 41: 203-10.
17. Mokart D, Slehofer G, Lambert J et al. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med 2014; 40: 41-9.
18. Khasawneh FA, Karim A, Mahmood T et al. Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome. Infection 2014; 42: 829-34.
19. Leone M, Bechis C, Baumstarck K et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40: 1399-408.
20. Vergis EN, Yu VL. New directions for future studies of communityacquired pneumonia: optimizing impact on patient care. Eur J Clin Microbiol Infect Dis 1999; 18: 847-51.
21. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122: 130-41.
22. Kozma CM, Dickson M, Raut MK et al. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP). J Med Econ 2010; 13: 719-27.
23. Dancer SJ. The problem with cephalosporins. J Antimicrob Chemother 2001; 48: 463-78.